146 results on '"Hermanus, Tandile"'
Search Results
2. Functional HIV-1/HCV cross-reactive antibodies isolated from a chronically co-infected donor
3. Neutralization titer biomarker for antibody-mediated prevention of HIV-1 acquisition
4. Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: an interim analysis of a randomised, double-blind, placebo-controlled, phase 1B/2A trial
5. SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma
6. Envelope characteristics in individuals who developed neutralizing antibodies targeting different epitopes in HIV-1 subtype C infection
7. Safety and immunogenicity of booster vaccination and fractional dosing with Ad26.COV2.S or BNT162b2 in Ad26.COV2.S-vaccinated participants
8. Protective efficacy of a plant-produced beta variant rSARS-CoV-2 VLP vaccine in golden Syrian hamsters
9. V2-Directed Vaccine-like Antibodies from HIV-1 Infection Identify an Additional K169-Binding Light Chain Motif with Broad ADCC Activity
10. Safety and immunogenicity of booster vaccination and fractional dosing with Ad26.COV2.S or BNT162b2 in Ad26.COV2.S-vaccinated participants
11. Homologous Ad26.COV2.S vaccination results in reduced boosting of humoral responses in hybrid immunity, but elicits antibodies of similar magnitude regardless of prior infection
12. Despite delayed kinetics, people living with HIV achieve equivalent antibody function after SARS-CoV-2 infection or vaccination
13. Needle-Free Devices and CpG-Adjuvanted DNA Improve Anti-HIV Antibody Responses of Both DNA and Modified Vaccinia Ankara-Vectored Candidate Vaccines
14. Antibody-dependent cellular cytotoxicity against SARS-CoV-2 Omicron sub-lineages is reduced in convalescent sera regardless of infecting variant
15. Characterization of anti-HIV-1 neutralizing and binding antibodies in chronic HIV-1 subtype C infection
16. HIV Coinfection Provides Insights for the Design of Vaccine Cocktails to Elicit Broadly Neutralizing Antibodies
17. Fc effector activity and neutralization against SARS-CoV-2 BA.4 is compromised in convalescent sera, regardless of the infecting variant
18. SARS-CoV-2 prolonged infection during advanced HIV disease evolves extensive immune escape
19. Escape from recognition of SARS-CoV-2 variant spike epitopes but overall preservation of T cell immunity
20. Prior infection with SARS-CoV-2 boosts and broadens Ad26.COV2.S immunogenicity in a variant-dependent manner
21. SARS-CoV-2 specific B cell memory drives improved class switching and tissue homing responses to single dose Ad26.COV2.S vaccination in previously infected recipients
22. Durability of ChAdOx1 nCoV-19 (AZD1222) Vaccine and Hybrid Humoral Immunity Against Variants Including Omicron BA.1 and BA.4 Six Months after Vaccination: A Randomised, Phase 1b/2a Trial
23. Therapeutic effect of CT-P59 against SARS-CoV-2 South African variant
24. Assessment of an LSDV-Vectored Vaccine for Heterologous Prime-Boost Immunizations against HIV
25. Evolution of an HIV glycan-dependent broadly neutralizing antibody epitope through immune escape
26. Ultrapotent antibodies against diverse and highly transmissible SARS-CoV-2 variants
27. Prior infection with SARS-CoV-2 boosts and broadens Ad26.COV2.S immunogenicity in a variant dependent manner
28. Elicitation of Neutralizing Antibody Responses to HIV-1 Immunization with Nanoparticle Vaccine Platforms
29. Coordinated Fc-effector and neutralization functions in HIV-infected children define a window of opportunity for HIV vaccination
30. Neutralizing antibodies elicited by the Ad26.COV2.S COVID-19 vaccine show reduced activity against 501Y.V2 (B.1.351), despite protection against severe disease by this variant
31. A principle‐based approach to justify the use of HIV self‐testing in South Africa
32. Therapeutic effect of CT-P59 against SARS-CoV-2 South African variant
33. ChAdOx1 nCoV-19 (AZD1222) Vaccine in People Living With and Without HIV
34. SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma
35. Modifications to the HIV-1 SAAVI MVA-C vaccine improve in vitro expression and in vivo immunogenicity
36. Divergence of Delta and Beta Variants and SARS-CoV-2 Evolved in Advanced HIV Disease into Two Serological Phenotypes
37. A principle‐based approach to justify the use of HIV self‐testing in South Africa.
38. Immunogenicity of HIV-1 Vaccines Expressing Chimeric Envelope Glycoproteins on the Surface of Pr55 Gag Virus-Like Particles
39. Production and Immunogenicity of Soluble Plant-Produced HIV-1 Subtype C Envelope gp140 Immunogens
40. The adjuvant AlhydroGel elicits higher antibody titres than AddaVax when combined with HIV-1 subtype C gp140 from CAP256
41. HIV-1 superinfection can occur in the presence of broadly neutralizing antibodies
42. Sequential Immunization with gp140 Boosts Immune Responses Primed by Modified Vaccinia Ankara or DNA in HIV-Uninfected South African Participants
43. HIV-1 clade C escapes broadly neutralizing autologous antibodies with N332 glycan specificity by distinct mechanisms
44. Comparative Neutralization Sensitivity of Indian and South African HIV-1 Clade C Viruses to Plasma Antibodies from Chronically Infected Indian Donors
45. Multiple Pathways of Escape from HIV Broadly Cross-Neutralizing V2-Dependent Antibodies
46. Potent and Broad Neutralization of HIV-1 Subtype C by Plasma Antibodies Targeting a Quaternary Epitope Including Residues in the V2 Loop
47. Antibody-dependent cellular cytotoxicity against SARS-CoV-2 Omicron sub-lineages is reduced in convalescent sera, regardless of the infecting variant
48. Escape from recognition of SARS-CoV-2 variant spike epitopes but overall preservation of T cell immunity
49. Comparative Neutralization Sensitivity of Indian and South African HIV-1 Clade C Viruses to Plasma Antibodies from Chronically Infected Indian Donors.
50. The Neutralization Breadth of HIV-1 Develops Incrementally over Four Years and Is Associated with CD4+ T Cell Decline and High Viral Load during Acute Infection.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.